How Is It Related to Cancer, and What Can Be Done About It?
SDH is a protein that is based in the mitochondria. Its loss causes a major energy and metabolic crisis. Despite this, some types of cells can ‘benefit’ from the loss of SDH and continue to grow uncontrollably and generate tumors.
Identifying metabolic enzymes as molecular drug targets that are uniquely essential for the survival of SDH-deficient cells is a key first step in the development of new therapies for SDH-deficient tumors. Some of these druggable enzymatic targets are being actively pursued.
Dr. Eyal Gottlieb will break down the biology of cells and discuss metabolism and growth during cancer formation.
This webcast is geared for patients and families with SDH-deficient GIST and other tumors.
There will be at 15 min Q&A at the end of his presentation.
To submit questions that could potentially be addressed during the webcast, please submit to Sara Rothschild at email@example.com by September 1.
For some background on cancer metabolism, review this document.
Dr. Eyal Gottlieb
Laura and Isaac Perlmutter Chair of Cancer Research, Faculty of Medicine
Technion – Israel Institute of Technology
Technical Tips to Join Meeting:
- This is a web only meeting, accessed only by your internet connection. Participants are encouraged to use the web link automatically provided after registration and to use computer speakers (and/or headsets if available) to hear the audio portion of the meeting. Please log in at least ten minutes prior to the start of the webinar.
- Please ensure you have an updated version of Adobe Flash Player (Google Chrome has Flash built in).
- If you are using a mobile device or tablet, in order to view and hear the conference, download the ReadyTalk App from your App store.